Roche clinch­es EU ap­proval for MabThera in rare au­toim­mune in­di­ca­tion — will it boost dwin­dling sales amid biosimi­ar com­pe­ti­tion?

Roche is pil­ing up an­oth­er Eu­ro­pean ap­proval for its MabThera fran­chise just as biosim­i­lars are se­ri­ous­ly erod­ing sales of the cru­cial drug, bet­ter known in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER